Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
0.6000 x 10 0.7800 x 3
Pre-market by (Cboe BZX)
0.6233 -0.0114 (-1.80%) 03/26/25 [NASDAQ]
0.6000 x 10 0.7800 x 3
Pre-market 0.6233 unch (unch) 16:00 ET
Quote Overview for Wed, Mar 26th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.6200
Day High
0.6399
Open 0.6300
Previous Close 0.6347 0.6347
Volume 70,900 70,900
Avg Vol 252,540 252,540
Stochastic %K 28.12% 28.12%
Weighted Alpha -49.45 -49.45
5-Day Change +0.0028 (+0.45%) +0.0028 (+0.45%)
52-Week Range 0.5803 - 1.5300 0.5803 - 1.5300
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,852
  • Shares Outstanding, K 86,422
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,140 K
  • EBIT $ -26 M
  • EBITDA $ -25 M
  • 60-Month Beta 1.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.53
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.30
  • Most Recent Earnings $-0.07 on 03/07/25
  • Next Earnings Date 05/08/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.09
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5803 +7.41%
on 03/11/25
Period Open: 0.7139
0.7631 -18.32%
on 03/06/25
-0.0906 (-12.69%)
since 02/26/25
3-Month
0.5803 +7.41%
on 03/11/25
Period Open: 1.0009
1.0300 -39.49%
on 12/27/24
-0.3776 (-37.73%)
since 12/26/24
52-Week
0.5803 +7.41%
on 03/11/25
Period Open: 1.0100
1.5300 -59.26%
on 10/07/24
-0.3867 (-38.29%)
since 03/26/24

Most Recent Stories

More News
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...

ONCY : 0.6233 (-1.80%)
EXEL : 37.01 (-1.86%)
ONC.TO : 0.90 (-1.10%)
ALXO : 0.6796 (-5.24%)
CRDF : 3.54 (-6.84%)
VSTM : 6.40 (-2.59%)
Stocks in play: Oncolytics Biotech Inc

Announces reporting on highlights and financial results for Q4 and year-end 2024. With its lead candidate, ...

ONCY : 0.6233 (-1.80%)
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never been more...

ALLO : 1.5700 (-1.87%)
ONCY : 0.6233 (-1.80%)
TARA : 4.53 (-4.23%)
YMAB : 4.84 (-4.91%)
FATE : 0.8541 (-5.38%)
ONC.TO : 0.90 (-1.10%)
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on...

ONCY : 0.6233 (-1.80%)
ONC.TO : 0.90 (-1.10%)
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

/CNW/ -- USA News Group News Commentary – Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what's being...

ONCY : 0.6233 (-1.80%)
GNTA : 4.13 (+5.09%)
CELC : 10.44 (-0.67%)
NYT : 49.33 (+0.39%)
SLS : 1.1800 (-3.28%)
ONC.TO : 0.90 (-1.10%)
AMGN : 305.71 (-0.37%)
World Cancer Day Sparks Big Questions About Pollution, Genetics, and Innovation

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As World Cancer Day (Feb. 4) fades into the rearview, attention is shifting to the latest discussions...

ONCY : 0.6233 (-1.80%)
ZNTL : 1.7600 (-5.88%)
NYT : 49.33 (+0.39%)
ABSI : 2.90 (-5.54%)
GOVX : 1.3700 (unch)
ONC.TO : 0.90 (-1.10%)
GSK : 38.31 (-0.70%)
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 0.6233 (-1.80%)
ONC.TO : 0.90 (-1.10%)
Investors Eye Biotech Sector as Cancer Therapy Market Surges

/CNW/ -- USA News Group News Commentary – Amid the excitement surrounding Project Stargate—the $500 billion investment aimed at revolutionizing AI-driven data...

ONCY : 0.6233 (-1.80%)
RENB : 0.6741 (+1.37%)
POAI : 1.6000 (-5.33%)
DGX : 166.62 (+0.58%)
GRAL : 28.39 (-9.01%)
ONC.TO : 0.90 (-1.10%)
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make...

ONCY : 0.6233 (-1.80%)
ONC.TO : 0.90 (-1.10%)
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor types...

ONCY : 0.6233 (-1.80%)
ONC.TO : 0.90 (-1.10%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 0.6554
2nd Resistance Point 0.6476
1st Resistance Point 0.6355
Last Price 0.6233
1st Support Level 0.6156
2nd Support Level 0.6078
3rd Support Level 0.5957

See More

52-Week High 1.5300
Fibonacci 61.8% 1.1672
Fibonacci 50% 1.0552
Fibonacci 38.2% 0.9431
Last Price 0.6233
52-Week Low 0.5803

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies